PZPing Zhou

Ping Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ping Zhou has a total of 104 co-authors. Here are the top co-authors by number of shared publications:

  • Lin Zhu

    Department of Pediatric Nephrology and Rheumatology, Sichuan Clinical Research Center for Pediatric Nephrology, Sichuan Provincial Women’s and Children’s Hospital/ The Affiliated Women’s and Children’s Hospital of Chengdu Medical College, Chengdu, China

    8 shared publications
  • Jianrong Liao

    Department of Pediatric Nephrology and Rheumatology, Sichuan Provincial Maternity and Child Health Care Hospital, Sichuan Provincial Women’s and Children’s Hospital, Sichuan Clinical Research Center for Pediatric Nephrology

    3 shared publications
  • Tian Lan

    Department of Pharmacology, College of Pharmacy; State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD); the Laboratory of Cardiovascular Disease and Molecular Intervention Harbin Medical University Harbin China

    3 shared publications
  • Wai W. Cheung

    Division of Pediatric Nephrology, Rady Children's Hospital University of California San Diego California USA

    3 shared publications
  • Fengbi Jiang

    Sichuan Provincial Women’s and Children’s Hospital / The Affiliated Women’s and Children’s Hospital of Chengdu Medical College

    2 shared publications
  • Hui Zhu

    Department of Pediatrics, Sichuan Provincial Women's and Children's Hospital, The Affiliated Women's and Children's Hospital of Chengdu Medical College, No. 290 West Second Street, Shayan Road, Chengdu, 610045, China

    2 shared publications

Latest Publications

  • Open Access

    Animal (Rodent) models of kidney disease: a literature review

    by Dong Tian, Yihui Lan, Lin Zhu, Ping Zhou

  • Open Access

    Tubular ACSM3 controls fatty acid metabolism and safeguards against acute kidney injury in male mice

    by Fengping Zhang, Li Feng, Ting Xiang, Jinxi Li, Qimei Wu, Fan Guo, Lingzhi Li, Zhouke Tan, Ping Zhou, Lin Lin, et al.

    Kidney tubular epithelial cells exceptionally exhibit high energy demands and preferentially metabolize long-chain fatty acids via fatty acid oxidation (FAO), where the impairment of FAO represents a hallmark of acute kidney injury (AKI). However, the role of medium-chain fatty acid metabolism in kidney injury remains unexplored. Here, we identify that tubular acyl-CoA synthetase medium-chain family member 3 (ACSM3), the key enzyme responsible for medium-chain fatty acid activation, is significantly down-regulated in damaged kidneys of distinct AKI male mouse models and acute tubular necrosis patients. Unexpectedly, tubule-specific ACSM3 deletion improves renal dysfunction, pathological damage, and metabolic disturbances in AKI male mice. Mechanistically, tubular ACSM3 deficiency preserves free fatty acid pool and reduces medium-chain fatty acids utilization, where these unused medium-chain fatty acids as ligands can activate peroxisome proliferator-activated receptor alpha (PPARα) and further upregulate PPARα-associated fatty acid metabolic genes to repair injured kidneys. Notably, dietary supplementation of medium-chain fatty acids confers protective effects against AKI in male mice. Our findings highlight tubular ACSM3 as a potential therapeutic target to control renal fatty acid metabolism and provide preclinical evidence that medium-chain fatty acid supplementation safeguards against AKI.

  • Open Access

    Summary of best evidence on health education for pediatric urinary tract infections

    by Xuqiong Tan, Jianrong Liao, Fengbi Jiang, Yun Li, Ping Zhou

    Background: Pediatric urinary tract infections (UTIs) significantly affect children’s health and quality of life. Health education plays a key role in improving parental health literacy, treatment adherence, and recurrence prevention. This study aimed to systematically synthesize the best available evidence on health education for the prevention and management of pediatric UTIs to serve as a reference for clinical practice. Methods: Following the “6S” evidence resource model, an evidence search was conducted in a top-down manner across the following sources: BMJ Best Practice, UpToDate, National Institute for Health and Care Excellence (NICE), Guidelines International Network (GIN), National Guideline Clearinghouse (NGC), Registered Nurses’ Association of Ontario (RNAO), Canadian Medical Association (CMA), New Zealand Ministry of Health Guidance Library, MedLive, American Academy of Pediatrics (AAP), European Association of Urology (EAU), Cochrane Library, EMbase, Ovid MEDLINE, PubMed, Web of Science, CINAHL, China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP, and SinoMed. The search period covered from database inception to October 31, 2025. Two reviewers independently screened and evaluated the retrieved literature. Evidence was extracted and summarized according to the JBI evidence grading and recommendation system. Results: A total of 14 publications were finally included: 4 clinical decisions, 5 guidelines, 1 evidence summary, 3 expert consensuses, and 1 systematic review. Through evidence synthesis and integration, 42 best-evidence statements were developed across eight domains: disease awareness, symptom recognition, diagnosis and evaluation, urine specimen collection, imaging examinations, treatment and medication, recurrence prevention, and follow-up instructions. Conclusion: This best-evidence summary comprehensively synthesizes evidence-based health education for pediatric urinary tract infections. The rigorous methodology and broad content coverage provide valuable scientific guidance for healthcare professionals involved in UTI health education.


  • Open Access

    A novel EVC2 splice-site variant expands the mutational and phenotypic spectrum of Weyers acrofacial dysostosis

    by Ai Chen, Wenwen Zhang, Pingping Long, Ximin Chen, Ayuan Zhang, Hui Zhu, Lan Zeng, Fu Xiong, Jin Wang, Shuyao Zhu, et al.

    Weyers acrofacial dysostosis (WAD) is a rare autosomal dominant ciliopathy caused by heterozygous pathogenic variants in the EVC2 gene. The classic phenotype includes short stature, dental anomalies, and nail dysplasia. To date, all reported causative variants are truncating mutations located within the last exon (exon 22). In contrast, pathogenic variants in other regions, particularly splice-site variants, remain poorly characterized. The co-occurrence of WAD and epilepsy has rarely been documented. We performed exome sequencing in a proband with comorbid developmental and epileptic encephalopathy (DEE) and WAD features. A candidate splice-site variant was further investigated using an in vitro minigene splicing assay. Exome sequencing identified a de novo heterozygous splice-site variant in EVC2 (c.451-1G > T). Minigene analysis confirmed that this variant causes complete skipping of exon 4, predicted to lead to an in-frame deletion (p.Tyr151_Leu173del). To our knowledge, this is the first report of a pathogenic splice-site variant in this region of EVC2 associated with WAD and DEE. Our study expands the mutational spectrum of EVC2. It underscores the utility of exome sequencing coupled with functional assays for diagnosing complex cases.

  • Open Access

    A novel NSD2 pathogenic variant in a Chinese patient with Rauch-Steindl syndrome: a case report

    by Hui Zhu, Tingting Feng, Wenjing Dong, Shuyao Zhu, Jinlin Liu, Jin Wang, Ping Zhou, Zemin Luo

    Rauch-Steindl syndrome (RSS) is a very rare autosomal dominant disorder caused by pathogenic variants in the NSD2 gene, characterized by dysmorphic facial


  • Open Access

    Prohibitin 2 ameliorates cisplatin-induced acute kidney injury by modulating mitochondrial homeostasis

    by Qi Zhang, Xiaoyu Shi, Lu Yao, Ping Zhou, Wei Ding

    Acute kidney injury (AKI), associated with a major health burden globally, is frequently caused by nephrotoxic agents, specifically cisplatin. Prohibitin (PHB) 2, a highly conserved mitochondrial protein localized at the inner mitochondrial membrane, is key to maintaining mitochondrial respiration, cristae morphogenesis, and regulating cell death. Despite being extensively assessed in chronic kidney disease models, the role of PHB2 in AKI, particularly cisplatin-induced AKI, warrants further exploration. Here, we investigated the protective effects of PHB2 in cisplatin-induced AKI in in vitro and in vivo models. The results demonstrated that cisplatin upregulated PHB2 expression both in vitro and in vivo . Mechanistically, PHB2 deficiency exacerbated cisplatin-induced cell apoptosis and mitochondrial dysfunction, indicated by increased caspase-3 activity and reactive oxygen species (ROS) production, as well as mitochondrial membrane potential loss, in vitro . Our Western blot analysis results further validated PHB2’s involvement in autophagy processes within renal tubular cells. Nevertheless, PHB2 overexpression mitigated these detrimental effects, suggesting the protective role of PHB2 in cisplatin-induced AKI. In vivo , adeno-associated virus–mediated PHB2 overexpression reduced cisplatin-induced renal tubular injury and enhanced mitochondrial ultrastructure, supporting its potential therapeutic benefits. Taken together, our findings underscore the protective role of PHB2 in cisplatin-induced AKI, highlighting its potential as a therapeutic target for mitigating renal injury. Future studies elucidating the mechanisms underlying the protective effects of PHB2 and exploring its clinical implications in AKI management are warranted.


  • Open Access

    Risk prediction models for renal injury in children with IgA vasculitis: a systematic review and meta-analysis

    by Jianrong Liao, Xuqiong Tan, Fengbi Jiang, Lin Zhu, Ping Zhou

    The goal of this systematic review and meta-analysis was to provide references for future researchers on how to develop and implement predictive models for renal injury in paediatric IgA vasculitis (IgAV). Systematic review and meta-analysis of observational studies. We systematically searched databases including China National Knowledge Infrastructure (CNKI), Wanfang Database, China Science and Technology Journal Database (VIP), SinoMed, PubMed, Web of Science, Cochrane Library, and Embase for studies on the construction of predictive models for renal injury in children with IgAV, up until 24 November 2024. Two researchers independently screened the studies, extracted data, and assessed bias risk via the Prediction Model Risk of Bias Assessment Tool (PROBAST). STATA 16.0 software was used to conduct meta-analysis of the area under the curve (AUC) values of the models. A total of 1,157 studies were retrieved. And 11 studies met the inclusion criteria. The sample sizes ranged from 155 to 583, with a renal injury incidence of 26.7–63.8%. The most common predictors included age, recurrent or persistent purpura, immunoglobulin A (IgA), D-dimer, and serum albumin (ALB). The included studies showed good overall applicability, however all were highly biased, mainly because they used inadequate data sources and reported poorly in the area analyzed. The pooled AUC of the five models was 0.86 (95% CI: 0.80–0.92), demonstrating good predictive power. In spite of the fact that the renal injury prediction model was found to be somewhat predictive in children with IgAV, all of them had a high risk of bias according to the PROBAST checklist. For these predictive tools to be more robust and clinically applicable, new models with larger sample sizes, rigorous designs, and external validation should be developed in the future.


  • Open Access

    Novel variant in MYH9 in a child with proteinuria and thrombocytopenia: a case report and literature review

    by Dan-Feng Xie, Lin Zhu, Xiao-Meng Wang, Yun Li, Ping Zhou

    There is a lack of awareness of the diagnosis and treatment of MYH9-related disorder (MYH9-RD), which is an autosomal dominant disease with heterogeneous clinical manifestations. We summarized the clinical phenotype and reported a novel variant in MYH9 in a child with focal segmental glomerulosclerosis (FSGS) and reviewed the relevant literature to better understand MYH9-RD. Unlike previous cases, this patient exhibited IgA deposition in the mesangial region, suggesting need for further investigation into prognostic and therapeutic significance of this finding. To reduce the risk of MYH9-RD misdiagnosis, we recommend assessing mean platelet diameter and granulocyte inclusions in patients with unexplained proteinuria and refractory thrombocytopenia.


  • Open Access

    Ligusticum cycloprolactam ameliorates hyperuricemic nephropathy through inhibition of TLR4/NF-κB signaling

    by Zhe Chen, Rong Chen, Jiamin Wang, Lin Zhu, Jie Niu, Minghui Li, Kaireng Wu, Juxian Mo, Siqi Zheng, Bing Liu, et al.


  • Open Access

    Single‐Cell Analysis of Endothelial Cell Injury in IgA Nephropathy

    by Yong‐Chang Yang, Lin Zhu, Jing‐Ying Zhao, Bo Zhang, Xiao‐Meng Wang, Wai W. Cheung, Cheng‐Guang Zhao, Ping Zhou

    Background: The precise mechanisms responsible for renal injury in IgA nephropathy (IgAN) are not fully understood. Our study employed an extensive scRNA‐seq analysis of kidney biopsies obtained from individuals with IgAN, with a specific emphasis on investigating the involvement of renal endothelial cells.Methods: We obtained data from the Gene Expression Omnibus database and conducted bioinformatics analysis, which included enrichment analysis of differentially expressed genes, AUCell analysis, and high‐dimensional weighted gene co‐expression network analysis (hdWGCNA). The results of these analyses were further validated using human renal glomerular endothelial cells (HRGECs).Results: The ScRNA‐seq data uncovered notable variations in gene expression between IgAN and control kidney tissues. The enrichment analysis using AUCell demonstrated a high presence of adhesion molecules and components related to the mitogen‐activated protein kinase signaling pathway within the renal endothelial cells. Furthermore, through hdWGCNA analysis, it was discovered that interleukin (IL)‐6, Rac1, and cadherin exhibited associations with the renal endothelial cells. Stimulation of HRGECs with IL‐6/IL‐6 receptor resulted in a significant reduction in VE‐cad expression while inhibiting Rac1 led to a substantial decrease in Rac1‐GTP levels and an increase in VE‐cad expression.Conclusion: This study presents novel findings regarding the contribution of renal endothelial cells to the development of IgAN, as it demonstrates that IL‐6 negatively regulates VE‐cad expression in HRGECs via Rac1. These results highlight the significant involvement of renal endothelial cells in the pathogenesis of IgAN.